Albiglutide for Fat Loss
Weekly GLP-1 agonist fused to albumin; discontinued GSK product (Tanzeum/Eperzan).
Why Albiglutide for fat loss?
Albiglutide (Tanzeum in US, Eperzan in EU) was a recombinant fusion of two tandem GLP-1 (7-36) molecules with human albumin, developed by GSK and FDA-approved 2014. The HARMONY-OUTCOMES trial showed CV event reduction. GSK voluntarily withdrew the product worldwide in 2018 for commercial reasons despite favorable efficacy.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Albiglutide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Weekly dosing
- HbA1c reduction
- CV benefit (HARMONY)
Reference dosing by bodyweight
Anchored to the most-cited research dose (30000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 18700–25300 mcg |
| 60–75 kg / 132–165 lb | 22950–31050 mcg |
| 75–90 kg / 165–198 lb | 28050–37950 mcg |
| 90–105 kg / 198–231 lb | 33150–44850 mcg |
| >105 kg / >231 lb | 38250–51750 mcg |
Side effects to weigh against fat loss benefit
- Injection-site reaction
- Diarrhea
- Now discontinued
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.